Earlier this afternoon the rather exciting news broke that beginning in December Truvada will be approved for use as pre-exposure prophylaxis (PrEP) for HIV in France. France’s Minister for Social Affairs and Health, Marisol Touraine, made the announcement that her country will become the second in the world (after the US) to approve Truvada for this use, and the first to provide it free of cost.
Following the release of the latest Public Health England report on HIV in the UK, the National AIDS Trust (NAT) called on the National Health Service to “provide PrEP without delay.”
According to the latest figures, there were 3,360 new HIV diagnoses among gay and bisexual men in the UK in 2014—the highest number ever recorded.
Emphasising that “current prevention work is making no dent on these numbers,” the NAT joins a growing chorus of organisations and individuals urging the NHS to act swiftly to make Truvada available for pre-exposure prophylaxis (PrEP) in the UK.